Anti-angiogenic gene therapy in the treatment of malignant gliomas

Area of Science:

• Oncology
• Molecular Biology
• Neuroscience

Background:

• Dr. Judah Folkman's hypothesis on angiogenesis in tumor growth has been validated over four decades.
• Significant advances in tumor biology and cancer therapy have occurred, yet glioblastoma multiforme (GBM) median survival has seen little improvement.
• GBM is a highly angiogenic tumor, with some anti-angiogenic drugs in clinical trials or approved for other cancers.

Purpose of the Study:

• To review potential angiogenic targets in glioblastoma multiforme (GBM).
• To discuss vector methodologies for delivering therapeutic agents to GBM.
• To explore novel approaches for overcoming therapeutic challenges in GBM, including structure, immune microenvironment, and angiogenesis resistance.

Main Methods:

• Review of scientific literature on angiogenesis in glioblastoma multiforme.
• Analysis of current and potential therapeutic targets for GBM.
• Evaluation of gene delivery vector methodologies for brain tumors.

Main Results:

• Several anti-angiogenic drugs show promise for GBM, with bevacizumab already approved.
• GBM presents unique therapeutic challenges including its structure, immune microenvironment, and resistance to anti-angiogenic therapies.
• Improved gene expression and vector biodistribution are critical for overcoming these challenges.

Conclusions:

• Targeting angiogenesis remains a key strategy for glioblastoma multiforme treatment.
• Novel vector delivery systems and therapeutic approaches are necessary to enhance treatment efficacy.
• Overcoming GBM's inherent resistance mechanisms is crucial for improving patient survival.